

In the claims:

Please cancel claims 1-14.

Claims 1-14 (Canceled).

Please add the following new claims:

15. (New) A bicistronic construct comprising coding sequences encoding polypeptides having p53 and p14ARF tumor suppressor activity.

16. (New) The bicistronic construct of claim 15, wherein said coding sequences are under the control of a single promoter.

17. (New) A vector comprising the bicistronic construct of claim 15, wherein said vector is selected from the group of vectors consisting of retroviral, adeno-associated viral, herpes simplex viral and cytomegaloviral vectors.

18. (New) A delivery vehicle comprising the bicistronic construct of claim 15, wherein said delivery vehicle is selected from the group consisting of liposomes, polylysine carrier complexes and naked DNA.

19. (New) A pharmaceutical composition comprising the bicistronic construct of claim 15.

20. (New) A pharmaceutical composition comprising the vector of claim 15.

21. (New) A pharmaceutical composition comprising the delivery vehicle of claim 15.

22. (New) A method of inducing killing or apoptosis of malignant or metastatic cancer cells, comprising contacting said cells with the bicistronic construct of claim 15, whereby killing or apoptosis of said malignant or metastatic cells is induced.

23. (New) The method of claim 22, wherein said coding sequences are under the control of a single promoter.

24. (New) The method of claim 22, wherein said bicistronic construct is in a vector, wherein said vector is selected from the group of vectors consisting of retroviral, adeno-associated viral, herpes simplex viral and cytomegaloviral vectors.

25. (New) The method of claim 22, wherein said bicistronic construct is in a delivery vehicle, wherein said delivery vehicle is selected from the group consisting of liposomes, polylysine carrier complexes and naked DNA.

26. (New) The method of claim 22, wherein said bicistronic construct is in a pharmaceutical composition.

27. (New) The method of claim 22, further comprising administering said bicistronic construct in combination with one or more modes of therapy selected from the group consisting of radiation therapy and chemotherapy.

28. (New) The method of claim 22, wherein said cancer cell is selected from the group consisting of head and neck cancer cells, breast cancer cells, lung cancer cells, colon tumor cells, liver tumor cells, brain tumor cells, kidney tumor cells, skin tumor cells, ovarian tumor cells, and prostate tumor cells.

29. (New) A method of inducing growth arrest of malignant or metastatic cancer cells, comprising contacting said cells with the bicistronic construct of claim 15, whereby growth arrest of said malignant or metastatic cells is induced.

30. (New) The method of claim 29, wherein said coding sequences are under the control of a single promoter.

31. (New) The method of claim 29, wherein said bicistronic construct is in a vector, wherein said vector is selected from the group of vectors consisting of retroviral, adeno-associated viral, herpes simplex viral and cytomegaloviral vectors.

32. (New) The method of claim 29, wherein said bicistronic construct is in a delivery vehicle, wherein said delivery vehicle is selected from the group consisting of liposomes, polylysine carrier complexes and naked DNA.

33. (New) The method of claim 29, wherein said bicistronic construct is in a pharmaceutical composition.

34. (New) The method of claim 29, further comprising administering said bicistronic construct in combination with one or more modes of therapy selected from the group consisting of radiation therapy and chemotherapy.

35. (New) The method of claim 29, wherein said cancer cell is selected from the group consisting of head and neck cancer cells, breast cancer cells, lung cancer cells, colon tumor cells, liver tumor cells, brain tumor cells, kidney tumor cells, skin tumor cells, ovarian tumor cells, and prostate tumor cells.